Mindray's Wuhan Subsidiary Absorbed in Merger and Secures Series A Funding

Previously, the company had issued an announcement of deregistration filing, with the reason for deregistration being merger or division.

The company was established in December 2019, with Han Le as the legal representative. It has a registered capital of 2 billion RMB and its business scope includes the production of Class I medical devices, sales of Class II medical devices, and the research and development of intelligent robots. The company is wholly owned by Mindray.

According to Qichacha News, on December 8,Wuhan Mindray Scientific Co., Ltd. Completes Series A FinancingMindray Medical takes over Mindray Technology Holdings to become the largest shareholder of Wuhan Mindray.

As early as a few months ago, Wuhan Mindray Scientific Co.,Ltd. releasedAbsorption MergerAnnouncement from Wuhan Mindray Scientific Co., Ltd.

Before the merger: Wuhan Mindray Scientific Co., Ltd. has a registered capital of 300 million yuan; Wuhan Mindray Biomedical Technology Co., Ltd. has a registered capital of 2 billion yuan.

After the merger: The registered capital of Wuhan Mindray Scientific Co., Ltd. was changed to 2.3 billion yuan.

At the same time,The legal representative of Wuhan Mindray Scientific Co., Ltd. has also been changed from Shi Peng to Han Le.

Wuhan Mindray Scientific Co.,Ltd.Headquartered in Wuhan, as aFocus on the development and research of orthopedic consumables and medical devicesThe technology enterprise, with profound technical accumulation and professional strength in the industry. Behind the equity and management changes lies Mindray's deep resource integration strategy in the Wuhan area.

Mindray's move is to strategically optimize resources, focus on the R&D of high-end medical equipment, and avoid the drag on growth from fierce industry competition.

On August 5, 2025, Mindray's global second headquarters – the Mindray Wuhan Base, with a total investment of 4.5 billion yuan, officially opened.The base covers two core sub-projects: Wuhan Research Institute and Production Manufacturing Base.

Wuhan Research Institute Positions Itself as a Mega R&D Center, Focusing on Biomedical Engineering R&D Fields. It Conducts Multiple Key Research Projects Including Biological Raw Materials and Reagent R&D, Surgical Equipment R&D, and Comprehensive Health Technology R&D, Providing Solid Support for Mindray's Technological Innovation and Product Upgrades.

The Wuhan production and manufacturing base is mainly responsible for the production, manufacturing, and business services of medical equipment and biological raw materials, ensuring the efficient transformation of products from research and development to mass production.

Mindray's emphasis on Wuhan may be attributed not only to the city's high investment value but also to Chairman Li Xiting's "sentiment" towards Wuhan.Li Xiting worked at the Wuhan Institute of Physics, engaging in physics research from 1976 to 1981 and again from 1984 to 1987.Li Xiting's nearly ten years of experience and understanding have strengthened Mindray's ties with Wuhan.

Li Xiting previously stated in an interview: "Wuhan has a large pool of talent from local universities and is more suitable for young people to settle down."